2''-O-Rhamnosylicariside II

CAS No. 135293-13-9

2''-O-Rhamnosylicariside II( —— )

Catalog No. M29607 CAS No. 135293-13-9

2''-O-Rhamnosylicariside II is beneficial for improving postmenopausal osteoporosis. It shows potent antioxidant activity, with IC50 values of 90.5 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 178 Get Quote
10MG 290 Get Quote
25MG 485 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    2''-O-Rhamnosylicariside II
  • Note
    Research use only, not for human use.
  • Brief Description
    2''-O-Rhamnosylicariside II is beneficial for improving postmenopausal osteoporosis. It shows potent antioxidant activity, with IC50 values of 90.5 uM.
  • Description
    2''-O-Rhamnosylicariside II is beneficial for improving postmenopausal osteoporosis. It shows potent antioxidant activity, with IC50 values of 90.5 uM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    135293-13-9
  • Formula Weight
    660.66
  • Molecular Formula
    C33H40O14
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (151.36 mM)
  • SMILES
    C[C@@H]([C@@H]([C@H]([C@H]1O)O)O)O[C@H]1O[C@H]([C@@H]1O)[C@H](OC2=C(c(cc3)ccc3OC)Oc(c(CC=C(C)C)c(cc3O)O)c3C2=O)O[C@@H](C)[C@@H]1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Kemptide

    Kemptide is a synthetic heptapeptide, acting as a substrate for cAMP-dependent protein kinase (PK).

  • Cipropride S enantio...

    Cipropride S enantiomer is the S enantiomer of cipropride which is an antiemetic drug.

  • Syk Inhibitor II hyd...

    The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus.